| Date | Title | Description | |
|---|---|---|---|
| 25 Feb 2025 | On P&L | The Company releases the press release related to the full year 2024 financial results | Download |
| 07 Feb 2025 | On P&L | The Company informs on some of the results expected by the market consensus | Download |
| 07 Nov 2024 | On P&L | The Company releases the press release related to the first nine months 2024 financial results | Download |
| 07 Nov 2024 | On P&L | The Company releases the first nine months 2024 financial results presentation | Download |
| 24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 17 Jun 2026 | Announcement of general shareholders’ meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting. | Download |
| 06 May 2026 | Announcement of general shareholders’ meeting | The Company announces the calling of its 2026 Ordinary General Shareholder´s Meeting. | Download |
| 01 Apr 2026 | On corporate transactions | ROVI announces the closing of the Asset Purchase Agreement entered into in September 2025 for the acquisition of a pharmaceutical manufacturing facility in Phoenix, Arizona (USA) | Download |
| 25 Feb 2026 | Annual Corporate Governance Report | The Company submits the Annual Corporate Governance Report for fiscal year 2025. | Download |
| 25 Feb 2026 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2025 annual report regarding remuneration of the members of the Board of Directors. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |